https://www.selleckchem.com/products/kn-62.html
CONCLUSION The VHL mutation may predict tumor responses to YC-1, a HIF-1α inhibitor. BACKGROUND/AIM The resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib or erlotinib, is considered a major challenge in the treatment of patients with non-small cell lung cancer (NSCLC). Herein, we identified the critical roles of anterior gradient 2 (AGR2) in gefitinib (Gef) resistance of mutant NSCLC cells. MATERIALS AND METHODS Using datasets from a pair of NSCLC-sensitive and NSCLC-resistant cells,
Like
Comment
Share
